Novo to Build Diabetes Pen Plant in Iran as Sanctions EaseBy
Danish drugmaker to spend 70 million euros on new factory
Easing sanctions to boost economy and spending on healthcare
Novo Nordisk A/S, the world’s biggest maker of insulin, will build a plant to assemble its FlexPen pre-filled devices in Iran to expand in a country where millions suffer from diabetes, two months after an international accord on sanctions relief.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.